Shocking fact: Despite being available for over two decades, a groundbreaking study reveals that a mere quarter of reproductive health experts in the U.S. actively prescribe self-administered injectable contraception. Many are even unaware it exists!
This is a major issue. The study, published on January 8th in Obstetrics & Gynecology, is the first to thoroughly examine the hurdles preventing widespread adoption of this potentially empowering birth control method.
Dr. Jennifer Karlin, a UCSF associate professor and the study's senior author, highlights the core problem: "Since most physicians don't know that this is an option, patients don't know about it." She emphasizes its safety, effectiveness, and the control it gives patients, urging open discussions and unbiased offerings.
The research surveyed 422 clinicians who regularly prescribe birth control. Astonishingly, only about a third of those familiar with the self-administered option actually prescribe it. The reasons for this reluctance are varied, including concerns about patients' ability to self-inject, uncertainty about pharmacy availability, and a lack of standardized patient counseling and prescription guidelines.
So, what exactly is this underutilized option? It's depot medroxyprogesterone acetate (DMPA), a synthetic form of the hormone progestin, delivered via injection. It prevents pregnancy for up to three months by stopping ovulation, thickening cervical mucus, and thinning the uterine lining.
DMPA comes in two forms: an intramuscular injection (Depo Provera), administered by a healthcare provider, and a subcutaneous version, injected just under the skin. The subcutaneous option is designed for self-administration, similar to the increasingly popular GLP-1 weight-loss drugs.
But here's where it gets controversial... Potential side effects, such as reduced bone mineral density, weight gain, and even a benign brain tumor called meningioma, have been linked to the drug. While the overall risk is low, it underscores the critical need for thorough discussions between clinicians and patients about the benefits and risks.
Approved in 2004, the subcutaneous version is officially labeled for clinician administration, yet healthcare providers have been successfully training patients in self-injection for years. Interestingly, self-injectable contraception is far more common globally, particularly in sub-Saharan Africa. Its use saw a rise in the U.S. during the COVID-19 pandemic, with over half the prescribers surveyed learning about it between 2020 and 2022.
International and national guidelines advocate for making this option accessible to all. However, the study revealed that providers in states with restricted abortion access were less likely to prescribe it. Other obstacles include insufficient educational materials, a lack of staff support, and limited consultation time with patients.
To broaden access, the study authors recommend an educational campaign for clinicians on self-administration. They also suggest FDA approval for the self-administered version, insurance coverage, and streamlined clinic workflows.
The study was supported by a grant from the Society of Family Planning.
What are your thoughts? Do you think this self-administered option should be more widely available? Are you surprised by the low prescription rates? Share your opinions in the comments below! Let's start a conversation about empowering women with more birth control choices.
